{"title":"携带候选抗微生物药物跨越死亡之谷:关键里程碑:决定继续或何时停止看似有希望的候选抗生素的开发是一个反复的练习","authors":"J. Fox","doi":"10.1128/microbe.11.155.1","DOIUrl":null,"url":null,"abstract":"What does a company need to do when a promising antimicrobial drug candidate turns up as part of a concerted research and development (R&D) program? First and foremost, said George Drusano of the University of Florida, Gainesville, “You need a hero to push the molecule forward.” However, if the molecule fails to meet critical milestones during that push forward, no matter how good it looked earlier, he added, “At some point, you need to put ‘old yeller’ down.”","PeriodicalId":87479,"journal":{"name":"Microbe (Washington, D.C.)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Carrying Antimicrobial Candidates across the Valley of Death: Key Milestones: Deciding to continue or when to halt development of seemingly promising antibiotic candidates is an iterative exercise\",\"authors\":\"J. Fox\",\"doi\":\"10.1128/microbe.11.155.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"What does a company need to do when a promising antimicrobial drug candidate turns up as part of a concerted research and development (R&D) program? First and foremost, said George Drusano of the University of Florida, Gainesville, “You need a hero to push the molecule forward.” However, if the molecule fails to meet critical milestones during that push forward, no matter how good it looked earlier, he added, “At some point, you need to put ‘old yeller’ down.”\",\"PeriodicalId\":87479,\"journal\":{\"name\":\"Microbe (Washington, D.C.)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Microbe (Washington, D.C.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1128/microbe.11.155.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbe (Washington, D.C.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/microbe.11.155.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Carrying Antimicrobial Candidates across the Valley of Death: Key Milestones: Deciding to continue or when to halt development of seemingly promising antibiotic candidates is an iterative exercise
What does a company need to do when a promising antimicrobial drug candidate turns up as part of a concerted research and development (R&D) program? First and foremost, said George Drusano of the University of Florida, Gainesville, “You need a hero to push the molecule forward.” However, if the molecule fails to meet critical milestones during that push forward, no matter how good it looked earlier, he added, “At some point, you need to put ‘old yeller’ down.”